Abbott Laboratories (ABT)

62.37
NYSE : Health Technology
Prev Close 62.51
Day Low/High 62.06 / 62.58
52 Wk Low/High 43.83 / 64.60
Avg Volume 6.17M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 109.59B
EPS 0.30
P/E Ratio 297.67
Div & Yield 1.12 (1.76%)

Latest News

Newest Generation Of Leading Heart Stent Is Now Approved In The U.S. For People With Coronary Artery Disease

- XIENCE Sierra™, the newest generation of XIENCE drug-eluting stents, received U.S. Food and Drug Administration (FDA) approval

Abbott's Investigational Tendyne™ Device For Mitral Valve Replacement Demonstrates Positive Outcomes At 30 Days In Global Study

- Promising results for Tendyne valve presented as late-breaking clinical trial at EuroPCR

Updates on Honeywell, Abbot and Nvidia

Conference highlights from Honeywell bolster the investment case.

Five-Year Study Data Confirm Positive Outcomes For Patients When Abbott Diagnostic Tool Was Used To Guide Heart Stenting Decisions

- Late-breaking data presented at EuroPCR and simultaneously published in "The New England Journal of Medicine" support use of Abbott's PressureWire™ guidewire to help physicians make stenting decisions

Weekly Roundup

Markets consolidate after recent gains

Jim's Daily Rundown

Jim discusses Macy's quarter as a readthrough to Nordstrom, defense and North Korea, and more on the market!

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

Being Bullish on Trump Surprisingly Worked Well for Investors This Week

President Trump reduced tensions in Korea, raised them in the Middle East, and mainly relieved them for investors in the drug and healthcare industries.

Weekly Roundup

The markets strongly rebounded this week as a few of the major averages pushed into positive year-to-date territory.

Weekly Roundup

A strong Friday failed to keep markets in positive territory.

Abbott Expands Cardiac Arrhythmias Portfolio With FDA Clearance Of Advanced Mapping Catheter

- ADVISOR™ HD GRID MAPPING CATHETER, SENSOR ENABLED™ FACILITATES IMPROVED DATA COLLECTION, SUPPORTING OPTIMAL TREATMENT FOR PATIENTS WITH COMPLEX CARDIAC ARRHYTHMIAS

Abbott's XIENCE Sierra™ Heart Stent Receives National Reimbursement In Japan To Treat People With Coronary Artery Disease

- Provides patients with access to latest-generation gold-standard heart stent through Japan's health insurance system

Weekly Roundup

Markets end flat for week as strong earnings fail to excite investors.

Four Additions and One Removal From the Bullpen

On a rough day for markets we review new additions to our investing bullpen.

Sanquin Selects Abbott's "Alinity™ S" Solution For Blood And Plasma Screening

LONG-TERM AGREEMENT BETWEEN SANQUIN, A LEADER IN BLOOD SERVICES, AND ABBOTT, A GLOBAL LEADER IN TRANSFUSION MEDICINE, HELPS ENSURE A SAFE AND EFFICIENT BLOOD SUPPLY IN THE NETHERLANDS

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains

Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains

Stocks finish mixed on Wednesday amid a sharp decline in IBM shares.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts look at banks, three sections to trade, and REITs.

Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'

Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'

FreeStyle Libre already has over 50,000 users in the U.S. since being approved for sale in the U.S. last September.

Jim's Daily Rundown

Jim discusses latest results for Abbott Labs, Goldman Sachs and more.

Abbott Labs Reports Top and Bottom Beat

Overall, it was a very solid quarter by Abbott.

Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance

Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance

Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.

Why I'm Not Piling 'All In' to the Banks: Market Recon

Why I'm Not Piling 'All In' to the Banks: Market Recon

Market reactions have ranged anywhere from lackluster to outright negative. What gives?

IBM, Morgan Stanley, Southwest - 5 Things You Must Know Before the Market Opens

IBM, Morgan Stanley, Southwest - 5 Things You Must Know Before the Market Opens

U.S. stock futures rise modestly; IBM tumbles after it reports a weaker-than-expected profit margin; the NTSB says the blown engine on a Southwest plane had 'metal fatigue.'

Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings

Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings

Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Is Newell Brands Worth the Fight?: Cramer's Top Takeaways

Is Newell Brands Worth the Fight?: Cramer's Top Takeaways

Not every battle is worth fighting, says Jim Cramer. That's especially true if you own shares of Newell Brands.

Vistra Energy Generating Cash Flow: Cramer's Top Takeaways

Vistra Energy Generating Cash Flow: Cramer's Top Takeaways

Curtis Morgan, president and CEO of Vistra Energy, talks to Jim Cramer about the outlook for coal and renewables.

TheStreet Quant Rating: B- (Buy)